Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

carbamazepine

AVLOIRE

carbamazepine (AVLOIRE) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 20
Pipeline programs 54
News articles 1
Drug details — carbamazepine
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
54
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

carbamazepine (AVLOIRE) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN carbamazepine
Brand AVLOIRE
Mechanism Sodium channel alpha subunit blocker
Target Sodium channel alpha subunit
Route ORAL
Formulation TABLET
Originator Novartis Pharmaceuticals

Mechanism of action

Sodium channel alpha subunit blocker

Primary target: Sodium channel alpha subunit

Approval history

Authority Status Date
FDA approved —
TGA approved —

Recent coverage

View all news
FDA Approves Lumasiran for PH1: What BD and Investors Should Know
Critical impact NewsAcute Hepatic PorphyriaJun 8, 2026

FDA Approves Lumasiran for PH1: What BD and Investors Should Know

FDA · Acute Hepatic Porphyria · 8 min

This rewrite clarifies that FDA-approved Givlaari (givosiran) is indicated for adults with acute hepatic porphyria, while OXLUMO (lumasiran) is approved for PH1. The article should frame the catalyst as a regulatory and portfolio update, not a new AHP label for lumasiran.

Dr. Sarah Mitchell

Pipeline programs

Search pipeline Sponsor programs
  1. 115747 Phase 3 · Disc Medicine · Metastatic renal cell carcinoma
  2. 20170770 Phase 3 · Amgen · Chemotherapy-induced Thrombocytopenia in Adult subjects with
  3. 2025-I2M-C&T-B-090B Phase 3 · Chinese Academy of · Pneumocystis Jiroveci Pneumonia
  4. 206785 Phase 3 · GSK Glaxo Smith · Severe asthma with an eosinophilic phenotype
  5. 221530 Phase 3 · GSK Glaxo Smith · Neoplasms, Head and Neck
  6. 221672 Phase 3 · GSK Glaxo Smith · Lung Diseases, Interstitial
  7. 222725 Phase 3 · GSK Glaxo Smith · Chronic Obstructive Pulmonary Disease
  8. 224295 Phase 3 · GSK Glaxo Smith · Chronic Obstructive Pulmonary Disease

Related & competitor drugs

Browse all drugs
  1. disopyramide phosphate Sodium channel alpha subunit blocker
  2. eslicarbazepine acetate Nervous system (N03)
  3. fosphenytoin sodium Sodium channel alpha subunit blocker
  4. lacosamide Nervous system (N03)
  5. lamotrigine Sodium channel alpha subunit blocker
  6. lidocaine Nervous system (N01)

Related patents

Browse patents Novartis Pharmaceuticals patent hub

  1. WO 2026112397

    COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE VIRUS ADÉNO-ASSOCIÉS

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026085433

    PROCÉDÉS POUR PRÉPARER DES CONJUGUÉS OLIGONUCLÉOTIDIQUES

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026060131

    ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026055127

    PROCÉDÉ DE PRODUCTION D'UN MODULATEUR DE RÉCEPTEUR GABA

    Expires Wed Mar 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12384779

    Bicyclic compounds

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025165930

    MÉTHODES DE TRAITEMENT DE L'AMYOTROPHIE SPINALE

    Expires Wed Aug 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12331126

    OX40-binding polypeptides and uses thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2025111408

    COMPOSÉS POUR LE TRAITEMENT DE L'AMYOTROPHIE SPINALE ET DE LA MALADIE DE HUNTINGTON

    Expires Thu May 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2025111409

    COMPOSÉS HÉTÉROCYCLIQUES DE FORMULE (I) DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'AMYOTROPHIE SPINALE PAR MODULATION DE L'ÉPISSAGE DE SMN2

    Expires Thu May 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2025106633

    INHIBITEURS DE TYK2

    Expires Wed May 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2025049275

    INHIBITEURS DE LA PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS

    Expires Wed Mar 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2025043148

    INHIBITEURS DE PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS

    Expires Wed Feb 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2025038863

    DÉRIVÉS D'INDOLE ET DE PYRROLOYPYRIDINE UTILISÉS EN TANT QUE MODULATEURS DE GPR17

    Expires Wed Feb 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12180192

    Modulators of THR-β and methods of use thereof

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2024259178

    INHIBITEURS DE GLYCOGÈNE SYNTHASE KINASE 3 ET LEURS UTILISATIONS

    Expires Wed Dec 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2024233374

    COMBINAISON D'UN INHIBITEUR DE BTK ET D'UN ESTER D'ACIDE FUMARIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES

    Expires Wed Nov 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2024233379

    INHIBITEUR DE BTK POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES

    Expires Wed Nov 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. WO 2024216080

    RÉGIMES IMMUNOSUPPRESSEURS ET PROCÉDÉS ASSOCIÉS

    Expires Wed Oct 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12083081

    Sterile aqueous choline salt compositions

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12084502

    CD33-binding polypeptides and uses thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is carbamazepine?

carbamazepine (AVLOIRE) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for carbamazepine?

AVLOIRE is a marketed brand name for carbamazepine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of carbamazepine?

carbamazepine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.